Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
EU Regulatory Roundup, May 2023: MDR Extension Updates Resume
May saw a resurgence of EU MDR news, following a few quieter weeks. Guidance on demonstrating compliance with extended transition periods and compiling clinical investigation reports were among the top-read articles in Medtech Insight in the past month.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
Cybersecurity Skills Shortage In EU ‘Untenable’ Warns Medtech Trade Body
EU medtech companies are subject to many legislative requirements that ensure devices are cybersecure, but more investment in digital literacy is needed to keep Europe safe from cyber breaches, MedTech Europe says in a new policy paper.
Genomic Tests Eliminate ‘Diagnostic Odysseys’ ̶ Why Are They Underutilized In The UK?
Genomic diagnostics provide significant value to the health system, but England’s unclear funding pathways and commissioning processes are preventing these tests from reaching patients, a report by trade body BIVDA reveals.
What Does The EU Regulation On HTA Mean For Medtech And When Will It Apply?
Several updates have come in recent weeks on the European Commission’s planned new Regulation on HTA, including a list of stakeholder members and updated rolling timeline. Medtech Insight explains how and when this legislation will affect the medtech sector.
MHRA Issues Guidance On Recognizing And Reporting Medtech Software Adverse Events
When it comes to medtech adverse events incidents may not always be obvious. This is especially the case with medical device software where indirect harm is the most likely outcome of an incident, the UK’s MHRA explains in new guidance.